AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Ascentage Pharma management to participate in investor conferences in September.
ByAinvest
Monday, Aug 25, 2025 8:02 am ET1min read
Ascentage Pharma Group International will participate in three investor conferences in September 2025. The events include Citi's 2025 Biopharma Back to School, Cantor Global Healthcare Conference 2025, and H.C. Wainwright 27th Annual Global Investment Conference. The live webcast of the Citi and Cantor events can be accessed on the company's website.
Ascentage Pharma Group International has announced its participation in three prominent investor conferences in September 2025. The company will be present at Citi's 2025 Biopharma Back to School Conference, Cantor Global Healthcare Conference 2025, and H.C. Wainwright 27th Annual Global Investment Conference. The live webcasts of the Citi and Cantor events will be accessible on the company's investor relations website.The Citi's 2025 Biopharma Back to School Conference will be held on September 2, 2025, at 4 p.m. ET in Boston, MA, featuring a fireside chat. The Cantor Global Healthcare Conference 2025 is scheduled for September 4, 2025, at 11:30 a.m. ET in New York, NY, also in the form of a fireside chat. The H.C. Wainwright 27th Annual Global Investment Conference will take place on September 9, 2025, at 9:30 a.m. ET in New York, NY, with a fireside chat format.
These conferences provide valuable opportunities for Ascentage Pharma Group International to engage with investors, discuss its pipeline of novel therapies, and share updates on its ongoing clinical trials. The company's participation underscores its commitment to transparency and investor relations.
References:
[1] https://ir.olema.com/news-releases/news-release-details/olema-oncology-participate-upcoming-investor-conferences-7
[2] https://en.coinotag.com/galaxy-multicoin-and-jump-may-seek-1-billion-solana-treasury-with-cantor-fitzgerald-as-lead-banker/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet